Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRIS-IPF Phase 2a study of PLN-74809 in idiopathic pulmonary fibrosis
NL-OMON54907Phase 2Completed
- Sponsor
- Pliant Therapeutics
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bexotegrast in idiopathic pulmonary fibrosis (IPF) (7 arms), sponsored by Pliant Therapeutics. Primary endpoint: Safety and tolerability. Started Mar 2020; status: completed.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON54907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54907.